遗传性乳腺癌风险基因检测与咨询：NCCN指南解读与瑞金医院临床实践

doi:10.16139/j.1007-9610.2024.05.06

外科理论与实践 ›› 2024, Vol. 29 ›› Issue (05): 401-404.doi: 10.16139/j.1007-9610.2024.05.06

遗传性乳腺癌风险基因检测与咨询：NCCN指南解读与瑞金医院临床实践

韩梦圆, 陈小松()

上海交通大学医学院附属瑞金医院普外科乳腺疾病诊治中心，上海 200025

收稿日期:2024-01-08 出版日期:2024-09-25 发布日期:2025-01-23
通讯作者: 陈小松，E-mail: chenxiaosong0156@hotmail.com

Hereditary breast cancer risk gene assessment and counseling: interpretation of NCCN guidelines and Ruijin Hospital clinical practice

HAN Mengyuan, CHEN Xiaosong()

Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received:2024-01-08 Online:2024-09-25 Published:2025-01-23

摘要/Abstract

摘要：

遗传性乳腺癌相关基因突变显著增加女性乳腺癌的发病风险，对此，美国国立综合癌症网络（NCCN）制定了《遗传/家族高风险评估指南》以指导这类基因突变携带者的遗传风险评估和咨询，为乳腺癌的预防、筛查和治疗提供必要信息。本文结合上海交通大学医学院附属瑞金医院的临床实践经验对《遗传/家族高风险评估指南》进行解读。

关键词: 乳腺癌, 遗传风险基因, 基因突变, NCCN指南, 实践

Abstract:

Hereditary breast cancer-related gene mutations significantly increase the risk of breast cancer in women. In this regard, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Genetic/Familial High-Risk Assessment was developed to guide genetic assessment and counseling in mutation carriers of breast cancer risk genes, providing crucial information for the prevention, screening and treatment of breast cancer. This article provided an interpretation of the NCCN Clinical Practice Guidelines in Genetic/Familial High-Risk Assessment, integrating the clinical practice experience of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.

Key words: Breast cancer, Hereditary risk gene, Gene mutation, NCCN guidelines, Practice

中图分类号:

R737.9

韩梦圆, 陈小松. 遗传性乳腺癌风险基因检测与咨询：NCCN指南解读与瑞金医院临床实践[J]. 外科理论与实践, 2024, 29(05): 401-404.

HAN Mengyuan, CHEN Xiaosong. Hereditary breast cancer risk gene assessment and counseling: interpretation of NCCN guidelines and Ruijin Hospital clinical practice[J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 401-404.

图/表 1

参考文献 15

[1]	Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours[J]. Nature, 2012, 490(7418):61-70.
[2]	DALY M B, PAL T, MAXWELL K N, et al. NCCN Guidelines^® Insights: Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024[J]. J Natl Compr Canc Netw, 2023, 21(10):1000-1010.
[3]	LANCASTER J M, POWELL C B, CHEN L M, et al. Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions[J]. Gynecol Oncol, 2015, 136(1):3-7. doi: 10.1016/j.ygyno.2014.09.009 pmid: 25238946
[4]	COHEN SA, BRADBURY A, HENDERSON V, et al. Genetic counseling and testing in a community setting: qua-lity, access, and efficiency[J]. Am Soc Clin Oncol Educ Book,2019,39:e34-e44.
[5]	FORREST L E, YOUNG M A. Clinically significant germline mutations in cancer-causing genes identified through research studies should be offered to research participants by genetic counselors[J]. J Clin Oncol, 2016, 34(9):898-901. doi: 10.1200/JCO.2015.60.9388 pmid: 26786918
[6]	ROBSON M, IM S A, SENKUS E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6):523-533.
[7]	LITTON J K, RUGO H S, ETTL J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J]. N Engl J Med, 2018, 379(8):753-763.
[8]	TUTT A N J, GARBER J E, KAUFMAN B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer[J]. N Engl J Med, 2021, 384(25):2394-2405.
[9]	Breast Cancer Association Consortium; MAVADDAT N, DORLING L, CARVALHO S, et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes[J]. JAMA Oncol, 2022, 8(3):e216744.
[10]	XICOLA R M, LI S, RODRIGUEZ N, et al. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria[J]. J Med Genet, 2019, 56(12):838-843.
[11]	HENDRICKS L A J, HOOGERBRUGGE N, VENSELAAR H, et al. Genotype-phenotype associations in a large PTEN Hamartoma Tumor Syndrome (PHTS) patient cohort[J]. Eur J Med Genet, 2022, 65(12):104632.
[12]	Breast Cancer Association Consortium; DORLING L, CARVALHO S, ALLEN J, et al. Breast cancer risk genes - association analysis in more than 113,000 women[J]. N Engl J Med, 2021, 384(5):428-439.
[13]	UUSITALO E, RANTANEN M, KALLIONPÄÄ R A, et al. Distinctive cancer associations in patients with neurofibromatosis type 1[J]. J Clin Oncol, 2016, 34(17):1978-1986. doi: 10.1200/JCO.2015.65.3576 pmid: 26926675
[14]	VAN LIER M G, WAGNER A, MATHUS-VLIEGEN E M, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations[J]. Am J Gastroenterol, 2010, 105(6):1258-1264. doi: 10.1038/ajg.2009.725 pmid: 20051941
[15]	ZHANG J, WANG N, ZHENG T, et al. Germline mutational landscape in Chinese patients with advanced breast cancer[J]. Front Oncol, 2022,12:745796.

遗传性乳腺癌风险基因检测与咨询：NCCN指南解读与瑞金医院临床实践

Hereditary breast cancer risk gene assessment and counseling: interpretation of NCCN guidelines and Ruijin Hospital clinical practice

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 15

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐旺旺1,2，许良凤1,2，刘宁徽3，律娜3. 基于多注意力卷积神经网络的乳腺癌组织学图像诊断[J]. J Shanghai Jiaotong Univ Sci, 2025, 30(1): 91-106.
[2]	关新平, 张志军, 姜海波, 张婷, 顾智超. 装备数字工程概念与实践思考[J]. 空天防御, 2024, 7(5): 1-7.
[3]	许明武, 聂炜. 国家翻译实践视域下我国古代科技翻译实践探赜——以官方翻译机构为中心的考察[J]. 当代外语研究, 2024, 24(4): 16-31.
[4]	宋达疆, 张天怡, 王志远, 等. 分叶游离下腹部皮瓣移植乳房再造的血管吻合方式选择 [J]. 组织工程与重建外科杂志, 2024, 20(4): 428-.
[5]	杜可君. 外语教育学视阈下的外语教学实践:超越语法[J]. 当代外语研究, 2024, 24(2): 118-126.
[6]	林玉珍. 数据库平台驱动下的翻译实践课程思政与国家意识强化[J]. 当代外语研究, 2024, 24(2): 58-69.
[7]	郝昆, 孙宇光, 王仁贵, 等. 抽吸减容术治疗乳腺癌术后上肢淋巴水肿[J]. 组织工程与重建外科杂志, 2024, 20(1): 69-.
[8]	孙毅, 周恬恬. 国家翻译实践论视域下的隐喻英译管窥[J]. 当代外语研究, 2024, 24(1): 125-135.
[9]	赵鑫, 高鹏, 陈洁. 机器人辅助手术系统在乳腺癌治疗中的应用及前景[J]. 外科理论与实践, 2024, 29(05): 376-381.
[10]	曹希, 骆勇超, 沈松杰. 适合中国女性的乳腺癌筛查策略[J]. 外科理论与实践, 2024, 29(05): 382-388.
[11]	笪倩, 阮淼, 费晓春, 王朝夫. 人工智能在乳腺癌病理诊断中的应用及研究展望[J]. 外科理论与实践, 2024, 29(05): 389-395.
[12]	陆裕杰, 朱思吉. 《双磷酸盐和其他骨调节剂在乳腺癌辅助治疗中的应用：ASCO-OH(CCO)指南更新》解读[J]. 外科理论与实践, 2024, 29(05): 405-408.
[13]	张丰哲, 童一苇, 陈小松, 沈坤炜. 前哨淋巴结阴性乳腺癌病人非前哨淋巴结转移相关危险因素分析[J]. 外科理论与实践, 2024, 29(05): 409-413.
[14]	周丽华, 沈茹, 屈柯暄, 王爱华, 陈有会, 袁志敏. ABO血型基因第7外显子695 T>C突变导致B_w11亚型的研究[J]. 诊断学理论与实践, 2024, 23(04): 392-397.
[15]	唐筱璐, 华鑫, 曹璐, 陈佳艺. 21基因检测在早期乳腺癌辅助放疗中的应用[J]. 外科理论与实践, 2024, 29(03): 270-276.